Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Sarcoma. 27 results shown below.

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

[Complete title: A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 9145
Phase: I

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

[Complete title: Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)]
Principal Investigator: K.Scott Baker
Study Number: 9161
Phase: II

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

[Complete title: A Trial of Pembrolizumab in Combination with Doxorubicin as Treatment for Patients with Advanced Sarcomas]
Principal Investigator: Seth Pollack
Study Number: 9624
Phase: I/II

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma

[Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6015
Phase: I

Construction of a Metastatic Osteosarcoma Tissue Microarray
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B604

Genetic Risk Factors of Ewing Sarcoma
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B611

A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

[Complete title: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas]
Principal Investigator: Elizabeth Loggers
Study Number: 20132286
Phase: II

Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors

[Complete title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors]
Principal Investigator: Manoj Menon
Study Number: 9493
Phase: I

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

[Complete title: A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma]
Principal Investigator: Lee Cranmer
Study Number: A091202
Phase: II

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

[Complete title: A Phase I/ Randomized Phase II Study of MLN0128 Vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma]
Principal Investigator: Lee Cranmer
Study Number: A091304
Phase: I/II

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group

[Complete title: ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) and Local Data Collection]
Principal Investigator: Doug Hawkins, MD
Study Number: ACCRN07

BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

[Complete title: ADVL1411, PHASE 1/ 2 STUDY OF BMN 673 (IND# 121510), AN ORAL POLY(ADP-RIBOSE) POLYMERASE INHIBITOR, PLUS TEMOZOLOMIDE IN CHILDREN WITH REFRACTORY OR RECURRENT MALIGNANCIES]
Principal Investigator: Julie Park, MD
Study Number: ADVL1411
Phase: I/II

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

[Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab]
Principal Investigator: Julie Park, MD
Study Number: ADVL1412
Phase: I/II

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

[Complete title: AEWS07B1, A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS07B1
Phase: NA

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

[Complete title: AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1221
Phase: II

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

[Complete title: Phase 2 Study of Denosumab, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AOST1321
Phase: II

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

[Complete title: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)]
Principal Investigator: Doug Hawkins, MD
Study Number: ARST1321
Phase: II

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

[Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors]
Principal Investigator: Christina Baik
Study Number: 20161101
Phase: I/II

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

[Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides]
Principal Investigator: John Thompson, MD
Study Number: 20161740
Phase: I

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

[Complete title: Feasibility of Assessing Drug Response to Precise Local Injection of Anti-Cancer Drugs Using Presage’s CIVO™ Device in Soft Tissue Sarcoma Patients Undergoing Surgery]
Principal Investigator: Seth Pollack
Study Number: 9260
Phase: Pilot

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (WIRB#20142430)]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Trial of CMB305 and Atezolizumab in Patients With Sarcoma (IMDZ-C232)

[Complete title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9521
Phase: II

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

[Complete title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma]
Principal Investigator: Elizabeth Loggers
Study Number: 9612
Phase: II

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

[Complete title: ADVL1322, A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors]
Principal Investigator: Julie Park, MD
Study Number: ADVL1322
Phase: II

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

[Complete title: SC-4007,EZH-102, A Phase I Study of the EZH2 Inhibitor Tazemtostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma]
Principal Investigator: Erin Pinto
Study Number: SC-4007
Phase: I

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

[Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma]
Principal Investigator: Erin Pinto
Study Number: SC-4008
Phase: II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials